Viking Therapeutics
VKTXNASDAQHigh RiskDeveloping next-generation GLP-1 receptor agonists and thyroid hormone receptor beta agonists. Lead obesity program VK2735 is a dual GLP-1/GIP receptor agonist designed to compete with Eli Lilly's tirzepatide (Mounjaro/Zepbound) with potentially superior weight loss and a subcutaneous or oral formulation.
Market cap
Mid cap
Cash position
$930M as of Q4 2025
36 months runway
Revenue status
pre revenue
Pipeline assets
3 programs
What does Viking Therapeutics do?
Viking Therapeutics is one of the most talked-about small biotech companies in the market right now, and the reason is simple: they may have cracked the code on a weight-loss drug that rivals the best from Eli Lilly and Novo Nordisk — the two giants that currently dominate the obesity market. Their lead drug, VK2735, works similarly to Mounjaro/Zepbound (Lilly's blockbuster): it mimics two gut hormones called GLP-1 and GIP that tell your brain you're full and your body to burn fat. In a Phase 2 trial, patients lost an average of 14.7% of their body weight in just 13 weeks. To put that in context, most weight-loss drugs take 6-12 months to show that level of results. Extrapolating Viking's trajectory suggests their drug could potentially match the ~22% weight loss that Zepbound achieves over a longer period. But here's what really excites investors: Viking is also developing an oral (pill) version of the same drug. Right now, all the top weight-loss drugs are injections, which many patients hate. If Viking can deliver comparable weight loss in a pill form, it would be revolutionary. Early Phase 1 data for the pill version looked promising. The investment case is straightforward: if VK2735 works in Phase 3, Viking becomes an acquisition target. Pfizer, Roche, AstraZeneca — any large pharma company without an obesity franchise would likely pay a substantial premium to buy Viking rather than develop their own drug from scratch. The obesity market is projected to be worth over $100 billion, so there's plenty of room for a third major player. The risk is equally straightforward: this is a pre-revenue company with 90 employees betting everything on one molecule. Phase 2 results don't always hold up in Phase 3. And competing against Lilly and Novo is like a startup trying to out-Google Google.
What to watch
Oral VK2735 Phase 2 data is the single most important catalyst in H2 2026 — double-digit weight loss from a pill would be seismic
Phase 3 VENTURE enrollment pace — faster enrollment signals strong investigator interest and patient demand
Any M&A rumors or partnership announcements — Viking at this stage is a classic acquisition candidate
Competitor data from Amgen (MariTide), Structure Therapeutics (oral GPCR agonist), and Lilly (orforglipron) — these set the bar Viking must clear
Cash burn rate trajectory — can they complete Phase 3 with existing cash or will they need to raise?
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| VK2735 (subcutaneous) | Obesity / overweight with comorbidities | Phase 3 | 2027 (Phase 3 VENTURE topline) | ▼ |
| VK2735 (oral) | Obesity / overweight with comorbidities | Phase 2 | H2 2026 | ▼ |
| VK2809 | NASH/MASH (non-alcoholic steatohepatitis) | Phase 2 | Partnered or deprioritized relative to VK2735 | ▼ |
Investment thesis
Bull case
Viking has arguably the best Phase 2 obesity data of any company outside Lilly and Novo. VK2735 showed 14.7% weight loss at just 13 weeks — a rate that, if sustained, could match or beat Zepbound. The oral formulation is potentially even more valuable because it removes the injection barrier. With $930M in cash, they can fully fund Phase 3 without dilution. The obesity market is the largest new drug market in a generation at $100B+. Viking is the most likely acquisition target in the space — Pfizer, AstraZeneca, Roche, or any large pharma without an obesity franchise would pay a massive premium. Even at a $10B acquisition price, that represents significant upside from current levels.
Bear case
Viking is a 90-person company trying to compete against two of the largest pharmaceutical companies on Earth (Lilly and Novo). Phase 2 to Phase 3 is where most obesity drugs fail — smaller trials can look impressive while larger trials regress to the mean. The 13-week Phase 2 data doesn't tell us about durability, weight regain, or long-term safety. If Phase 3 results come in materially below Zepbound, Viking loses its competitive thesis entirely. The oral program is even earlier and oral GLP-1s have historically shown less weight loss than injectable forms. The $930M cash sounds like a lot, but running a global Phase 3 obesity trial costs $500M+. There's no revenue, no other approved products, and the entire company's value rests on one molecule.
Key upcoming catalysts
VK2735 oral Phase 2 data readout
H2 2026
VK2735 SC Phase 3 VENTURE enrollment completion
2026
Potential partnership or M&A activity
2026-2027
VK2735 SC Phase 3 VENTURE topline results
2027
Risk factors
Phase 3 obesity results come in below Phase 2 levels, which is common due to larger, more diverse patient populations
Oral VK2735 shows significantly less weight loss than injectable, undermining the oral thesis
Eli Lilly or Novo Nordisk launch next-gen products that raise the efficacy bar before Viking can reach market
Safety signals emerge in longer-duration studies that weren't apparent in 13-week Phase 2
No acquirer steps up, forcing Viking to commercialize independently — a massive operational challenge for a 90-person company
Comparable companies
Financial snapshot
Cash
$930M as of Q4 2025
Quarterly burn
$65M
Cash runway
36 months
Revenue
pre revenue
Institutional ownership
55%
Recent offering
$900M raised via equity offering in early 2024 to fund Phase 3 obesity program
Sponsored
Get premium VKTX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you